Navigation Links
NeurogesX to Present at UBS Global Life Sciences Conference

SAN MATEO, Calif., Sept. 17 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and Chief Executive Officer, is scheduled to present at the UBS Global Life Sciences Conference, to be held September 21 - 23, 2009 in New York City.

Mr. DiTonno and Stephen Ghiglieri, Chief Financial Officer, will also be available to respond to questions immediately following the presentation and to participate in one-on-one meetings with investors attending the conference.

Event: UBS Global Life Sciences Conference

Date: Wednesday, September 23, 2009

Time: 4:30 p.m. ET

Place: Grand Hyatt New York, New York City

The presentation will be webcast live and can be accessed by visiting the investor relations section of NeurogesX' website at The webcasts will be archived for 180 days.

About NeurogesX, Inc.

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza(TM), a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in the European Union for the treatment of neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain. Qutenza will be marketed in the European Union and certain countries in Eastern Europe, the Middle East and Africa, by Astellas Pharma Europe, Ltd. In the United States, NeurogesX submitted a new drug application (NDA) for PHN to the U.S. Food and Drug Administration (FDA) which was accepted for filing by the FDA in December 2008 and has been given an extended Prescription Drug User Fee Act (PDUFA) date of November 16, 2009.

NeurogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies and NeurogesX is currently planning the design and timing of this program.

NeurogesX' early stage product pipeline includes pre-clinical compounds, which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to the timing and outcome of regulatory decisions and label approval being sought or that may be obtained with respect to the NDA for Qutenza with the FDA, including the PDUFA date for the NDA; plans and timing for commercialization of Qutenza; and development activities for NGX-1998 and other product candidates, including regulatory submissions and any outcomes of such submissions. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: positive results in clinical trials may not be sufficient to obtain FDA approval; the FDA may request additional clinical trials or other information prior to granting approval for Qutenza; any regulatory approvals which are received may be limited to certain indications; NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy or tolerability; physician or patient reluctance to use Qutenza or NGX-1998, if approved; and other difficulties or delays in, clinical development of, and obtaining regulatory approval for NeurogesX' product candidates. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

    NeurogesX, Inc.
    Stephen Ghiglieri
    Chief Financial Officer
    (650) 358-3310

    The Ruth Group
    Sara Pellegrino (investors)
    (646) 536-7002

    Jason Rando (media)
    (646) 536-7025

SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NeurogesX to Present at Upcoming Fall Conferences
2. NeurogesX Appoints New Board Director and Audit Committee Chairman
3. NeurogesX Reports Second Quarter 2009 Results
4. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
5. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
6. NeurogesX Added to Russell 3000 Index
7. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
8. NeurogesX to Present at Needham Life Sciences Conference
9. NeurogesX Receives European Commission Approval for Qutenza(TM)
10. NeurogesX Reports First Quarter 2009 Results
11. NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... Global Stem Cells ... stages of a new closed system for isolating adipose-derived stem cells. The announcement starts ... (SVF) of adipose tissue. SVF is a component of the lipoaspirate obtained from liposuction ...
(Date:11/30/2015)...  An interventional radiology technique shows promise for helping morbidly ... a study being presented today at the annual meeting of ... (RSNA). --> --> ... radiologists as a way to stop bleeding in emergency situations, ... of treating obesity is new. Mubin Syed , ...
(Date:11/30/2015)... , Nov. 30, 2015  Culprits beware, ... assistant chemistry professor Jan Halámek, is taking crime ...   --> ...   --> --> ... UAlbany have discovered a straightforward concept for identifying ...
(Date:11/30/2015)... , Nov. 30, 2015 Spherix ... company committed to the fostering and monetization of ... current and prospective initiatives designed to create shareholder ... Executive Officer of Spherix. "Based on published reports, ... licensees exceeds $50 billion and Spherix will seek ...
Breaking Biology Technology:
(Date:11/19/2015)... , Nov. 19, 2015  Based on its ... & Sullivan recognizes BIO-key with the 2015 Global Frost ... year, Frost & Sullivan presents this award to the ... catering to the needs of the market it serves. ... line meets and expands on customer base demands, the ...
(Date:11/18/2015)...  As new scientific discoveries deepen our understanding of ... providers face challenges in better using that knowledge to ... as more children continue to survive pediatric cancer, that ... age. John M. Maris, M.D ., a ... (CHOP) . --> John M. Maris, ...
(Date:11/17/2015)... 17, 2015 Paris from ... --> Paris from 17 th until ... biometrics innovation leader, has invented the first combined scanner in ... same scanning surface. Until now two different scanners were required: ... can capture both on the same surface. This innovation ...
Breaking Biology News(10 mins):